1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Cellectis S.A.
  6. News
  7. Summary
    ALCLS   FR0010425595

CELLECTIS S.A.

(ALCLS)
  Report
Real-time Euronext Paris  -  05/17 03:57:08 am EDT
3.104 EUR   +3.67%
05/16Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
GL
05/16Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
AQ
05/13Barclays Lowers Cellectis S.A's Price Target to $7 From $9, Overweight Rating Maintained
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

01/18/2022 | 04:33am EDT

- Allogene reported that Chromosomal Abnormality Was Not the Result of TALEN® Gene Editing or Allogene's Manufacturing Process

- Allogene to Initiate a Phase 2 Pivotal Clinical Trial of ALLO-501A in Relapsed/Refractory Large B-cell Lymphoma Mid-year 2022 Pending FDA Discussion

New York (N.Y.) - Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today stated that its licensed partner, Allogene Therapeutics, Inc. (Nasdad: ALLO) announced that the U.S. Food and Drug Administration (FDA) has lifted the hold on its clinical trials.

The FDA had placed a clinical hold on all five of Allogene's clinical trials on October 7, 2021 following a report of a chromosomal abnormality detected in ALLO-501A CAR+ T-cells from a single patient enrolled in Allogene's ALPHA2 study. Allogene reported today that the investigations concluded that the chromosomal abnormality was unrelated to TALEN® gene editing or Allogene's manufacturing process and had no clinical significance. The abnormality was not detected in any manufactured AlloCAR T(TM) product or in any other patient treated with the same ALLO-501A lot. The abnormality occurred in the patient after the cell product was administered. It involved regions of the T cell receptor and immunoglobulin genes known to undergo rearrangement as part of the natural T cell or B cell maturation process.

"We are very pleased that our licensed partner Allogene is now able to resume its clinical trials, bringing us one step closer to delivering these innovative therapies to patients with unmet medical needs", said Dr. Andre Choulika, CEO of Cellectis. "TALEN® gene editing technologies were not involved in the findings leading to the clinical hold. More than 170 patients with relapsed or refractory malignancies have been administered TALEN®-edited allogeneic CAR-T cell product candidates with a favorable safety profile, making it the largest and most robust disclosed clinical dataset of any gene editing technology in the world."

Allogene also announced that following the lift of the clinical holds and pending final discussions with the FDA, Allogene intends to initiate a Phase 2 pivotal trial of ALLO-501A in relapsed/refractory large B-cell lymphoma mid-year 2022.

Allogene's allogeneic CAR-T programs utilize Cellectis' technologies. ALLO-501 and ALLO-501A are anti-CD19 products being jointly developed under a collaboration agreement between Servier and Allogene based on an exclusive license granted by Cellectis to Servier. Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S. while Servier retains exclusive rights for all other countries.

Allogene has an exclusive license to Cellectis' technologies for ALLO-715, ALLO-605 (both directed at BCMA) and ALLO-316 (directed at CD70) and holds development and commercial rights for these investigational product candidates.

.

(C) 2022 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
ALLOGENE THERAPEUTICS, INC. -2.07% 7.08 Delayed Quote.-52.55%
CELLECTIS S.A. 3.07% 3.104 Real-time Quote.-59.76%
All news about CELLECTIS S.A.
05/16Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGC..
GL
05/16Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGC..
AQ
05/13Barclays Lowers Cellectis S.A's Price Target to $7 From $9, Overweight Rating Maintaine..
MT
05/13TRANSCRIPT : Cellectis S.A., Q1 2022 Earnings Call, May 13, 2022
CI
05/12Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022
GL
05/12Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022
AQ
05/12CELLECTIS S.A. : 1st quarter results
CO
05/11European ADRs Move Sharply Higher in Wednesday Trading
MT
05/06European ADRs Move Lower in Friday Trading
MT
05/06Calyxt, Inc., Cellectis' Majority-Owned Subsidiary, Reports Its First Quarter 2022 Fina..
AQ
More news
Analyst Recommendations on CELLECTIS S.A.
More recommendations
Financials
Sales 2022 70,0 M 72,8 M 72,8 M
Net income 2022 -63,6 M -66,2 M -66,2 M
Net cash 2022 42,6 M 44,3 M 44,3 M
P/E ratio 2022 -1,35x
Yield 2022 -
Capitalization 136 M 142 M 142 M
EV / Sales 2022 1,34x
EV / Sales 2023 -1,34x
Nbr of Employees 297
Free-Float 84,3%
Chart CELLECTIS S.A.
Duration : Period :
Cellectis S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLECTIS S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 2,99 €
Average target price 16,00 €
Spread / Average Target 434%
EPS Revisions
Managers and Directors
André Choulika Chief Executive Officer & Director
Bing C. Wang Chief Financial Officer
Jean-Pierre Garnier Non-Executive Chairman
Philippe Duchateau Chief Scientific Officer
Carrie Brownstein Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CELLECTIS S.A.-59.76%142
MODERNA, INC.-46.35%54 199
LONZA GROUP AG-28.13%40 453
IQVIA HOLDINGS INC.-26.83%39 077
SEAGEN INC.-7.80%26 238
ICON PUBLIC LIMITED COMPANY-32.02%17 114